Management of chimeric antigen receptor T (CAR-T) cell-associated toxicities.
CAR-T
CAR-T complications
CRS
ICAHT
ICANS
Intensive Care
Journal
Intensive care medicine
ISSN: 1432-1238
Titre abrégé: Intensive Care Med
Pays: United States
ID NLM: 7704851
Informations de publication
Date de publication:
22 Aug 2024
22 Aug 2024
Historique:
received:
21
05
2024
accepted:
21
07
2024
medline:
22
8
2024
pubmed:
22
8
2024
entrez:
22
8
2024
Statut:
aheadofprint
Résumé
The use of chimeric antigen receptor T (CAR-T) cells is a significant therapeutic improvement increasing the prognosis for patients with a variety of hematological malignancies. However, this therapy has also sometimes life-threatening, complications. Therefore, knowledge of the treatment and management of these complications, especially in treatment centers and intensive care units, respectively, is of outstanding importance. This review provides recommendations for the diagnosis, management, and treatment of CAR-T cell-associated complications such as cytokine release syndrome, immune effector cell associated neurotoxicity syndrome, hematotoxicity, hypogammaglobulinemia, and CAR-T cell-induced pseudo-progression amongst others for physicians treating patients with CAR-T cell-associated complications and intensivists.
Identifiants
pubmed: 39172238
doi: 10.1007/s00134-024-07576-4
pii: 10.1007/s00134-024-07576-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Couzin-Frankel J (2013) Breakthrough of the year 2013. Cancer Immunotherap Sci 342(6165):1432–1433
June CH, Sadelain M (2018) Chimeric antigen receptor therapy. N Engl J Med 379(1):64–73
pubmed: 29972754
pmcid: 7433347
doi: 10.1056/NEJMra1706169
Shimabukuro-Vornhagen A, Gödel P, Subklewe M et al (2018) Cytokine release syndrome. J Immunother Cancer 6(1):56–70
pubmed: 29907163
pmcid: 6003181
doi: 10.1186/s40425-018-0343-9
Azoulay É, Castro P, Maamar A et al (2021) Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study. Lancet Haematol 8(5):e355–e364
pubmed: 33894170
doi: 10.1016/S2352-3026(21)00060-0
Sterner RC, Sterner RM (2021) CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J 11(4):69
pubmed: 33824268
pmcid: 8024391
doi: 10.1038/s41408-021-00459-7
Mailankody S, Devlin SM, Landa J et al (2022) GPRC5D-targeted CAR T cells for myeloma. N Engl J Med 387(13):1196–1206
pubmed: 36170501
pmcid: 10309537
doi: 10.1056/NEJMoa2209900
Garcia Borrega J, Gödel P, Rüger MA et al (2019) In the Eye of the Storm: Immune-mediated Toxicities Associated With CAR-T Cell Therapy. Hemasphere 3(2):191–200
doi: 10.1097/HS9.0000000000000191
Benmebarek MR, Karches CH, Cadilha BL, Lesch S, Endres S, Kobold S. Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells. Int J Mol Sci. 2019;20(6).
Pietrobon V, Todd LA, Goswami A, Stefanson O, Yang Z, Marincola F. Improving CAR T-Cell Persistence. Int J Mol Sci. 2021;22(19).
Honikel MM, Olejniczak SH. Co-Stimulatory Receptor Signaling in CAR-T Cells. Biomolecules. 2022;12(9).
Cappell KM, Kochenderfer JN (2021) A comparison of chimeric antigen receptors containing CD28 versus 4–1BB costimulatory domains. Nat Rev Clin Oncol 18(11):715–727
pubmed: 34230645
doi: 10.1038/s41571-021-00530-z
Esensten JH, Helou YA, Chopra G, Weiss A, Bluestone JA (2016) CD28 Costimulation: From Mechanism to Therapy. Immunity 44(5):973–988
pubmed: 27192564
pmcid: 4932896
doi: 10.1016/j.immuni.2016.04.020
Zhang X, Zhu L, Zhang H, Chen S, Xiao Y (2022) CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front Immunol 13:927153
pubmed: 35757715
pmcid: 9226391
doi: 10.3389/fimmu.2022.927153
Cameron J Turtle L-AH, Carolina Berger, Daniel Sommermeyer, Barbara Pender, Emily M Robinson, Katherine Melville, Tanya M Budiarto, Natalia N Steevens, Colette Chaney, Sindhu Cherian, Brent L Wood, Lorinda Soma, Xueyan Chen, Shelly Heimfeld, Michael C Jensen, Stanley R. Riddell, David G Maloney. Addition of Fludarabine to Cyclophosphamide Lymphodepletion Improves In Vivo Expansion of CD19 Chimeric Antigen Receptor-Modified T Cells and Clinical Outcome in Adults with B Cell Acute Lymphoblastic Leukemia. Blood. 2015;Volume 126(Issue 23):Page 3773.
Bracci L, Moschella F, Sestili P et al (2007) Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 13(2 Pt 1):644–653
pubmed: 17255288
doi: 10.1158/1078-0432.CCR-06-1209
Hay KA, Gauthier J, Hirayama AV et al (2019) Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood 133(15):1652–1663
pubmed: 30728140
pmcid: 6460418
doi: 10.1182/blood-2018-11-883710
Spooren A, Kolmus K, Laureys G et al (2011) Interleukin-6, a mental cytokine. Brain Res Rev 67(1–2):157–183
pubmed: 21238488
doi: 10.1016/j.brainresrev.2011.01.002
Schuster SJ, Maziarz RT, Rusch ES et al (2020) Grading and management of cytokine release syndrome in patients treated with tisagenlecleucel in the JULIET trial. Blood Adv 4(7):1432–1439
pubmed: 32271899
pmcid: 7160283
doi: 10.1182/bloodadvances.2019001304
Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant 25(4):625–638
pubmed: 30592986
doi: 10.1016/j.bbmt.2018.12.758
Kotch C, Barrett D, Teachey DT (2019) Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 15(8):813–822
pubmed: 31219357
pmcid: 7936577
doi: 10.1080/1744666X.2019.1629904
Heinz WJ, Buchheidt D, Christopeit M et al (2017) Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). Ann Hematol 96(11):1775–1792
pubmed: 28856437
pmcid: 5645428
doi: 10.1007/s00277-017-3098-3
Wang L, Lv Y, Zhou L et al (2024) Cytokine-based models for efficient differentiation between infection and cytokine release syndrome in patients with hematological malignancies. Exp Hematol Oncol 13(1):1–5
doi: 10.1186/s40164-024-00495-6
Luo H, Wang N, Huang L et al (2019) Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer 7(1):271
pubmed: 31640816
pmcid: 6806557
doi: 10.1186/s40425-019-0767-x
Topp M, Van Meerten T, Houot R, et al. Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma. Blood. 2019;134(Supplement_1):243–243.
Jain MD, Smith M, Shah NN (2023) How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood 141(20):2430–2442
pubmed: 36989488
pmcid: 10329191
Cecconi M, Parsons AK, Rhodes A (2011) What is a fluid challenge? Curr Opin Crit Care 17(3):290–295
pubmed: 21508838
doi: 10.1097/MCC.0b013e32834699cd
Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. Jama. 1995;274(8):639–644.
Gazeau N, Liang EC, Wu QV et al (2023) Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther 29(7):430–437
pubmed: 37031746
pmcid: 10330552
doi: 10.1016/j.jtct.2023.04.001
Garfall AL, Lancaster E, Stadtmauer EA et al (2016) Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. Blood 128(22):5702–5703
doi: 10.1182/blood.V128.22.5702.5702
Gust J, Taraseviciute A, Turtle CJ (2018) Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies. CNS Drugs 32(12):1091–1101
pubmed: 30387077
pmcid: 7295115
doi: 10.1007/s40263-018-0582-9
Rees JH. Part IV: Clinical Management of Patients Treated with CAR-T Cells. In: Kröger N. The EBMT/EHA CAR-T Cell Handbook.2022.
Patel S, Maria-Rios J, Parikh A, Okorie ON (2023) Diagnosis and management of elevated intracranial pressure in the emergency department. Int J Emerg Med 16(1):72–91
pubmed: 37833652
pmcid: 10571389
doi: 10.1186/s12245-023-00540-x
Möhn N, Bonda V, Grote-Levi L et al (2022) Neurological management and work-up of neurotoxicity associated with CAR T cell therapy. Neurol Res Pract 4(1):1
pubmed: 35000613
pmcid: 8744256
doi: 10.1186/s42466-021-00166-5
Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T (2008) Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 112(10):3959–3964
pubmed: 18784373
doi: 10.1182/blood-2008-05-155846
Lemoine J, Vic S, Houot R (2022) Disease-specific outcomes after chimeric antigen receptor T-cell therapy. Eur J Cancer 160:235–242
pubmed: 34865943
doi: 10.1016/j.ejca.2021.10.022
Farrokh S, Tahsili-Fahadan P, Ritzl EK, Lewin JJ 3rd, Mirski MA (2018) Antiepileptic drugs in critically ill patients. Crit Care 22(1):153–165
pubmed: 29880020
pmcid: 5992651
doi: 10.1186/s13054-018-2066-1
Wehrli M, Gallagher K, Chen YB, et al. Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS). J Immunother Cancer. 2022;10(1).
Cohen AD, Parekh S, Santomasso BD et al (2022) Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J 12(2):32
pubmed: 35210399
pmcid: 8873238
doi: 10.1038/s41408-022-00629-1
Wang Q, Gao J, Wu X (2018) Pseudoprogression and hyperprogression after checkpoint blockade. Int Immunopharmacol 58:125–135
pubmed: 29579717
doi: 10.1016/j.intimp.2018.03.018
Frelaut M, du Rusquec P, de Moura A, Le Tourneau C, Borcoman E (2020) Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy. BioDrugs 34(4):463–476
pubmed: 32394415
doi: 10.1007/s40259-020-00425-y
Seymour L, Bogaerts J, Perrone A et al (2017) iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol 18(3):e143–e152
pubmed: 28271869
pmcid: 5648544
doi: 10.1016/S1470-2045(17)30074-8
Boursier C, Perrin M, Bordonne M, Campidelli A, Verger A (2022) Early 18F-FDG PET Flare-up Phenomenon After CAR T-Cell Therapy in Lymphoma. Clin Nucl Med 47(2):e152–e153
pubmed: 34406181
doi: 10.1097/RLU.0000000000003870
Denton CC, Gange WS, Abdel-Azim H et al (2020) Bilateral retinal detachment after chimeric antigen receptor T-cell therapy. Blood Adv 4(10):2158–2162
pubmed: 32428218
pmcid: 7252550
doi: 10.1182/bloodadvances.2020001450
Mahdi J, Dietrich J, Straathof K et al (2023) Tumor inflammation-associated neurotoxicity. Nat Med 29(4):803–810
pubmed: 37024595
pmcid: 10166099
doi: 10.1038/s41591-023-02276-w
Majzner RG, Ramakrishna S, Yeom KW et al (2022) GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603(7903):934–941
pubmed: 35130560
pmcid: 8967714
doi: 10.1038/s41586-022-04489-4
Dunleavy K, Hakim F, Kim HK et al (2005) B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106(3):795–802
pubmed: 15718416
pmcid: 1895166
doi: 10.1182/blood-2004-08-3198
Fried S, Avigdor A, Bielorai B et al (2019) Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant 54(10):1643–1650
pubmed: 30809033
doi: 10.1038/s41409-019-0487-3
Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med 380(1):45–56
pubmed: 30501490
doi: 10.1056/NEJMoa1804980
Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol 20(1):31–42
pubmed: 30518502
doi: 10.1016/S1470-2045(18)30864-7
Rejeski K, Subklewe M, Aljurf M et al (2023) Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood 142(10):865–877
pubmed: 37300386
doi: 10.1182/blood.2023020578
Rejeski K, Perez A, Sesques P et al (2021) CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood 138(24):2499–2513
pubmed: 34166502
pmcid: 8893508
doi: 10.1182/blood.2020010543
Wang Y, Song Z, Geng Y et al (2022) The risk factors and early predictive model of hematotoxicity after CD19 chimeric antigen receptor T cell therapy. Front Oncol 12:987965
pubmed: 36249041
pmcid: 9561932
doi: 10.3389/fonc.2022.987965
Miller KC, Johnson PC, Abramson JS et al (2022) Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma. Blood Cancer J 12(10):146
pubmed: 36316312
pmcid: 9622902
doi: 10.1038/s41408-022-00741-2
Davis JA, Sborov DW, Wesson W et al (2023) Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther 29(9):567–571
pubmed: 37225044
doi: 10.1016/j.jtct.2023.05.012
Gilreath J, Lo M, Bubalo J (2021) Thrombopoietin Receptor Agonists (TPO-RAs): Drug Class Considerations for Pharmacists. Drugs 81(11):1285–1305
pubmed: 34160821
pmcid: 8318934
doi: 10.1007/s40265-021-01553-7
Gagelmann N, Wulf GG, Duell J et al (2023) Hematopoietic stem cell boost for persistent neutropenia after CAR T-cell therapy: a GLA/DRST study. Blood Adv 7(4):555–559
pubmed: 35696759
doi: 10.1182/bloodadvances.2022008042
Wat J, Barmettler S (2022) Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions. J Allergy Clin Immunol Pract 10(2):460–466
pubmed: 34757064
doi: 10.1016/j.jaip.2021.10.037
Kampouri E, Walti CS, Gauthier J, Hill JA (2022) Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: key points for clinicians. Expert Rev Hematol 15(4):305–320
pubmed: 35385358
doi: 10.1080/17474086.2022.2063833
Wudhikarn K, Palomba ML, Pennisi M et al (2020) Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. Blood Cancer J 10(8):79
pubmed: 32759935
pmcid: 7405315
doi: 10.1038/s41408-020-00346-7
Bhoj VG, Arhontoulis D, Wertheim G et al (2016) Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. Blood 128(3):360–370
pubmed: 27166358
pmcid: 4957161
doi: 10.1182/blood-2016-01-694356
Hill JA, Seo SK (2020) How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies. Blood 136(8):925–935
pubmed: 32582924
pmcid: 7441168
doi: 10.1182/blood.2019004000
Topp M, Feuchtinger T. Part IV Clinical Management of Patients Treated with CAR-T Cells. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H. The EBMT/EHA CAR-T Cell Handbook2022.
Hill JA, Li D, Hay KA et al (2018) Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy. Blood 131(1):121–130
pubmed: 29038338
pmcid: 5755046
doi: 10.1182/blood-2017-07-793760
Park JH, Romero FA, Taur Y et al (2018) Cytokine Release Syndrome Grade as a Predictive Marker for Infections in Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia Treated With Chimeric Antigen Receptor T Cells. Clin Infect Dis 67(4):533–540
pubmed: 29481659
doi: 10.1093/cid/ciy152
Hines MR, Knight TE, McNerney KO et al (2023) Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther 29(7):438.e431-438.e416
doi: 10.1016/j.jtct.2023.03.006
Sandler RD, Tattersall RS, Schoemans H et al (2020) Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP). Front Immunol 11:524
pubmed: 32296434
pmcid: 7137396
doi: 10.3389/fimmu.2020.00524
Henter JI, Horne A, Aricó M et al (2007) HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124–131
pubmed: 16937360
doi: 10.1002/pbc.21039
Bergsten E, Horne A, Aricó M et al (2017) Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130(25):2728–2738
pubmed: 28935695
pmcid: 5785801
doi: 10.1182/blood-2017-06-788349
Marar RI, Abbasi MA, Prathivadhi-Bhayankaram S et al (2023) Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. JCO Oncol Pract 19(6):331–342
pubmed: 36930845
doi: 10.1200/OP.22.00713
Nenna A, Carpenito M, Chello C, et al. Cardiotoxicity of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Pathophysiology, Clinical Implications, and Echocardiographic Assessment. Int J Mol Sci. 2022;23(15).
Ganatra S, Dani SS, Yang EH, Zaha VG, Nohria A (2022) Cardiotoxicity of T-Cell Antineoplastic Therapies: JACC: CardioOncology Primer. JACC CardioOncol 4(5):616–623
pubmed: 36636447
pmcid: 9830211
doi: 10.1016/j.jaccao.2022.07.014
Flugel CL, Majzner RG, Krenciute G et al (2023) Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. Nat Rev Clin Oncol 20(1):49–62
pubmed: 36418477
doi: 10.1038/s41571-022-00704-3
Young RM, Engel NW, Uslu U, Wellhausen N, June CH (2022) Next-Generation CAR T-cell Therapies. Cancer Discov 12(7):1625–1633
pubmed: 35417527
pmcid: 9262817
doi: 10.1158/2159-8290.CD-21-1683
Cohen AD, Mateos MV, Cohen YC et al (2023) Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents. Blood 141(3):219–230
pubmed: 36095849
doi: 10.1182/blood.2022015526